SBI Securities’s Elicio Therapeutics ELTX Stock Holding History

SBI Securities’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$151	Sell	83 -100	-55%	-$277	﹤0.01%	3482
2026 Q2	$716	Buy	183 +101	+123%	+$1.01K	﹤0.01%	2919
2026 Q1	$877	Hold	82	–	–	﹤0.01%	2705
2025 Q4	$653	Hold	82	–	–	﹤0.01%	2781
2025 Q3	$897	Sell	82 -1	-1%	-$10	﹤0.01%	2739
2025 Q2	$641	Hold	83	–	–	﹤0.01%	2860
2025 Q1	$511	Hold	83	–	–	﹤0.01%	2867
2024 Q4	$423	Buy	+83	New	+$409	﹤0.01%	2954

Other funds holding ELTX

Shah Capital Management Raleigh, North Carolina $605M AUM 43.69% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return

Moody Lynn & Lieberson Boston, Massachusetts $1.93B AUM 20.85% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

SBI Securities's ELTX Position: Q3 2026 in Review

SBI Securities reduced its Elicio Therapeutics (ELTX) stake by 55% in Q3 2026, selling an estimated $277 and leaving 83 shares worth $151. The position accounts for ﹤0.01% of the portfolio, ranked #3482.

SBI Securities first reported a position in ELTX in Q4 2024 and has held it in 8 quarters since. The position peaked at $897 in Q3 2025. 13 funds tracked by Wall St. Rank hold ELTX as of Q3 2026.

SBI Securities held 83 shares of Elicio Therapeutics worth $151 as of Q3 2026.
SBI Securities sold 100 Elicio Therapeutics shares in Q3 2026, an estimated $277.
Elicio Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #3482 holding.
SBI Securities first reported a position in Elicio Therapeutics in Q4 2024 and has held it in 8 quarters since.
SBI Securities's Elicio Therapeutics position peaked at $897 in Q3 2025.
13 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.